Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide
and rituximab in controlling the Follicular Lymphoma disease and also increase the length of
response compared to the available standard combination chemotherapy treatment for Follicular
Lymphoma.